

AMENDMENTS TO THE CLAIMS

1. (Original) A pharmaceutical composition comprising amorphous cefditoren pivoxil and a sugar ester fatty acid, which is obtainable by mixing or wet-granulating particles containing amorphous cefditoren pivoxil with the sugar ester fatty acid while amorphous cefditoren pivoxil maintains its particle state.

2. (Original) The pharmaceutical composition according to claim 1, which contains 0.1 to 100 mg of the sugar ester fatty acid on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

3. (Currently amended) The pharmaceutical composition according to claim 1 ~~or~~ 2, which further comprises a pharmaceutically acceptable polymer.

4. (Original) The pharmaceutical composition according to claim 3, wherein the polymer is one or more water-soluble high polymers selected from hydroxypropylmethyl cellulose, methylcellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, and hydroxypropyl cellulose.

5. (Currently amended) The pharmaceutical composition according to claim 3 ~~or~~ 4, which contains 1 to 100 mg of the polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

6. (Currently amended) The pharmaceutical composition according to ~~any one of claims 1 to 4~~ claim 1, which further comprises one or more pharmaceutically acceptable additives.

7. (New) The pharmaceutical composition according to claim 2, which further comprises a pharmaceutically acceptable polymer.

8. (New) The pharmaceutical composition according to claim 7, wherein the polymer is one or more water-soluble high polymers selected from hydroxypropylmethyl cellulose, methylcellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, and hydroxypropyl cellulose.

9. (New) The pharmaceutical composition according to claim 4, which contains 1 to 100 mg of the polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

10. (New) The pharmaceutical composition according to claim 7, which contains 1 to 100 mg of the polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

11. (New) The pharmaceutical composition according to claim 8, which contains 1 to 100 mg of the polymer on the basis of an amount equivalent to 100 mg efficacy of cefditoren pivoxil.

12. (New) The pharmaceutical composition according to claim 2, which further comprises one or more pharmaceutically acceptable additives.

13. (New) The pharmaceutical composition according to claim 3, which further comprises one or more pharmaceutically acceptable additives.

14. (New) The pharmaceutical composition according to claim 4, which further comprises one or more pharmaceutically acceptable additives.

15. (New) The pharmaceutical composition according to claim 7, which further comprises one or more pharmaceutically acceptable additives.

16. (New) The pharmaceutical composition according to claim 8, which further comprises one or more pharmaceutically acceptable additives.

17. (New) The pharmaceutical composition according to claim 9, which further comprises one or more pharmaceutically acceptable additives.

18. (New) The pharmaceutical composition according to claim 10, which further comprises one or more pharmaceutically acceptable additives.

19. (New) The pharmaceutical composition according to claim 11, which further comprises one or more pharmaceutically acceptable additives.